Command Palette

Search for a command to run...

Clinical Trials · NCT01982630

Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003)

CompletedPhase 1Liraglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Merck Sharp & Dohme LLC
Enrollment
87
Start date
Nov 2013
Locations
See registry
Primary endpoint
Number of Participants Experiencing Adverse Events (AEs) in Part 1
View Liraglutide compound reference